AS-3201. Aldose reductase inhibitor

Drugs of the Future

Volumn 25, Issue 2, 2000, Pages 131-136

  Ono, Yoshiyuki ^a   Negoro, Toshiyuki ^b   Komiya, Masanobu ^b  

^a Clinical Development   (Japan)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 BROMO 2 FLUOROBENZYL)SPIRO (1,2,3,4 TETRAHYDROPYRROLO[1,2 A]PYRAZINE 4,3' PYRROLIDINE) 1,2',3,5' TETRAONE; ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; FIDARESTAT; IMIRESTAT; MINALRESTAT; POLYOL; PONALRESTAT; RANIRESTAT; SORBINIL; TOLRESTAT; UNCLASSIFIED DRUG; ZENARESTAT; ZOPOLRESTAT;

CATARACT; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME BINDING; ENZYME INHIBITION; GLUCOSE METABOLISM; HUMAN; MOTOR NERVE; NERVE CONDUCTION; NONHUMAN; REVIEW;

EID: 0034070126     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.02.566373     Document Type: Review

References (19)

1. Negoro, T., Murata, M., Ueda, S., Fujitani, B., Ono, Y., Kuromiya, A., Komiya, M., Suzuki, K., Matsumoto, J. Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-Bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4- spiro-3′-pyrrolidine-1,2′,3,5′-tetrone (AS-3201) and its congeners. J Med Chem 1998, 41: 4118-29.
2. Pirart, J. Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978, 1: 168-88.
3. Ziegler, D., Mayer, P., Mühlen, H., Gries, F.A. The natural history of somatosensory and autonomic nerve dysfunction in relation to glycaemic control during the first 5 years after diagnosis of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1991, 34: 822-9.
4. Greene, D.A., Lattimer, S.A. Impaired rat sciatic nerve sodium-potassium adenosine triphosphatase in acute streptozotocin diabetes and its correction by dietary myo-inositol supplementation. J Clin Invest 1983, 72: 1058-63.
5. Van Dam, P.S., Van Asbeck, B.S., Erkelens, D.W., Marx, J.J.M., Gispen. W.H., Bravenboer, B. The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab Rev 1995, 11: 181-92.
6. +)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994, 94: 853-9.
7. Williamson, J.R., Chang, K., Frangos, M., Hasan, K.S., Ido, Y., Kawamura, T., Nyengaard, J.R., Van den Enden, M., Kilo, C., Tilton, R.G. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993, 42: 801-13.
8. Brownlee, M. Glycation and diabetic complications. Diabetes 1994, 43: 836-41.
9. Jaspan, J.B., Towle, V.L., Maselli, R., Herold, K. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. Metabolism 1986, 35(Suppl. 1): 83-92.
10. Foppiano, M., Lombardo, G. Worldwide pharmacovigilance systems and tolrestat withdrawal. Lancet 1997, 349: 399-400.
11. Greene, D.A., Sima, A.A.F. Effects of aldose reductase inhibitors on the progression of nerve damage. Diabet Med 1993, 10(Suppl. 2):S31-2.
12. Negoro, T., Murata, M., Ueda, S., Mizuta, H., Ono, Y., Fujitani, B., Matsumoto, J. A new aldose reductase inhibitor: Synthesis and biological activities of pyrrolo[1,2-a]pyrazine derivatives. 206th ACS Natl Meet (Aug 22-27, Chicago) 1993, Abst MEDI 238.
13. Ono, Y., Fujitani, B., Kuromiya, A., Nakamura, K., Komiya, M., Karasawa, T. Effect of a novel, highly potent aldose reductase inhibitor, SX-3201 in diabetic rats. 15th Int Diabetes Fed Cong (Nov 6-11, Kobe) 1994, Abst 10A5-0873.
14. Nakamura, K., Fujitani, B., Ono, Y., Komiya, M., Negoro, T., Kuromiya, A., Karasawa, T. Enzymological study of SX-3201, a potent and long-lasting aldose reductase inhibitor. Can J Physiol Pharmacol 1994, 72(Suppl. 1): Abst P5.2.32.
15. Kurono, M., Yoshida, K., Naruto, S. Interaction between SX-3201, a potent aldose reductase (AR) inhibitor, and recombinant human AR. 209th ACS Natl Meet (April 2-6, Anaheim) 1995, Abst MEDI 197.
16. Pfeifer, M.A., Schumer, M.P., Gelber, D.A. Aldose reductase inhibitors: The end of an era or the need for different trial designs? Diabetes 1997, 46(Suppl. 2): S82-89.
17. Cameron, N.E., Cotter, MA Dissociation between biochemical and functional effects of the aldose reductase inhibitor, ponalrestat, on peripheral nerve in diabetic rats. Br J Pharmacol 1992, 107: 939-44.
18. 14C]SX-3201, an aldose reductase inhibitor, in rats. 4th Int ISSX Meet (Aug 27-31, Seattle) 1995, Abst 313.
19. Cameron, N.E., Cotter, M.A. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997, 46(Suppl. 2): S31-7.